We are on a journey to advance epicutaneous immunotherapy, using our innovative technology platform, Viaskin™
We are exploring the first epicutaneous immunotherapy (EPIT™) treatment for peanut allergy
We plan to explore a potential new class of immunotherapy to transform the lives of people with unmet medical needs
DBV’s robust development program includes ongoing clinical trials. Viaskin’s potential to re-educate the immune system makes it a promising approach beyond food allergies.
Comprehensive clinical research program in place, including Phase 3, long-term studies
Completed a Phase 1/2 trial to study safety and efficacy in pediatric and adolescent patients
Completed a Phase 2a study sponsored by the Children’s Hospital of Philadelphia (CHOP)
Our novel Viaskin patch is based on investigational EPIT. This potential new class of immunotherapy is designed to induce an immune response by introducing minimal amounts of antigen to the skin.
We are developing the Viaskin technology platform to help improve the lives of patients diagnosed with peanut and other food allergies.
An estimated 8% of children in the U.S., or approximately 2 children in every classroom, have a food allergy
Peanut allergy is one of the most common food allergies, and can cause severe, potentially fatal, allergic reactions, as well as anaphylaxis.
In Europe, about 17 million people are affected by food allergies, including 3.5 million under the age of 25.
Research suggests that only about 20% of people with peanut allergy are expected to outgrow it during their lifetime
Between 1994 and 2005 Australia experienced a 350% increase in hospital admissions for food-related anaphylaxis episodes, mostly in children under the age of five
News • 10/18/2021
Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2021Download PDF